A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation (SCIG-MG)

Inclusion Criteria:

* Patients between18 to 80 years of age, diagnosed with MG (see below) who have worsening myasthenic symptoms - (defined as increasing diplopia, ptosis, dysarthria, dysphagia, difficulty chewing, or limb weakness severe enough to warrant immunoglobulin therapy.
* MG diagnosis will be based upon the clinical evaluation by a neuromuscular expert and meeting any two of the following supportive criteria:

  1. Abnormal Tensilon test
  2. Abnormal repetitive nerve stimulation studies
  3. Abnormal single fiber electromyography (EMG)
  4. Increased serum acetylcholine receptor or anti-MuSK antibodies
  5. Prior response to immunotherapy

Exclusion Criteria:

1. Respiratory distress requiring ICU admission or a vital capacity \<1 L
2. Severe swallowing difficulties with a high risk of aspiration
3. Change in corticosteroid dosage in the 4 weeks prior to screening
4. Known immunoglobulin A (IgA) deficiency
5. Pregnant or breast feeding women
6. Active renal or hepatic insufficiency, clinically significant cardiac disease
7. Patients with worsening weakness associated with an infectious process
8. Previous lack of responsiveness to IVIG
9. History of previous MG crises